Thomas Thum
Thomas Thum is an expert in Cardiology at Hannover Medical School (Germany). As of October 2026, ScienceLeadR ranks Thomas Thum in the top 1% of experts worldwide for Heart Failure. Thomas Thum has authored 647 publications, the most recent in 2026, and is an investigator in 7 clinical trials. SLR score: 2,730 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Pharmacy - Biochemistry - Genetics
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2003 - 2026
Number : 647
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Nucleoside-Modified mRNA Encoding Alpha-Galactosidase A Ameliorates Fabry Disease Phenotypes in Human IPSC-Derived Cardiomyocytes. PMID 42591063 — galactosidases, alpha-galactosidase, biomedical research, heart, phenotype, rna, messenger, nucleosides, calcium, glycosphingolipids, therapeutics, cardiomyopathies, fabry disease, myocytes, cardiac, phospholamban | Adv Sci (Weinh) | 2026 | 0 |
| Generation of human induced pluripotent stem cell line MHHi040-A from a female Fabry disease patient carrying c.644A>G missense mutation. PMID 42492409 — cells, genes, microscopy, electron, scanning transmission, alpha-galactosidase, pluripotent stem cells, mutation, missense, stem cells, cell line, induced pluripotent stem cells, mutation, fabry disease | Stem Cell Res | 2026 | 0 |
| Integrated Multi-omics Analysis Uncovers Molecular Dysregulation in Glycosylceramide Synthase-Deficient Human Induced Pluripotent Stem Cells. PMID 42492790 — cells, genes, microscopy, electron, scanning transmission, pluripotent stem cells, multiple chronic conditions, stem cells, ceramides, glycosphingolipids, induced pluripotent stem cells, teratoma, proteome | Mol Cell Proteomics | 2026 | 0 |
| Loss of lncRNA H19 impairs neonatal cardiac regeneration. PMID 42345349 — infant, newborn, heart, rna, long noncoding | Am J Physiol Cell Physiol | 2026 | 0 |
| Preclinical evaluation of cysteine protease-inhibitor aloxistatin (E64d) for heart failure therapy. PMID 42343037 — cysteine, heart failure, pharmaceutical preparations, heart, cysteine proteinase inhibitors, clinical medicine, peptide hydrolases, protease inhibitors, therapeutics, cysteine proteases, preclinical evaluation | J Mol Med (Berl) | 2026 | 0 |
Clinical Studies 7
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
LeadR Networks
Main global connection map